Gilead Sciences (GILD) 103.69 $GILD 4 Top-Rated

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 12:31 PM

Gilead Sciences (GILD) 103.69 $GILD

4 Top-Rated Drugmakers Reporting Earnings This Week
at Investor's Business Daily - Sun Apr 26, 7:02AM CDT
This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up...
IMS: 29.00 (+1.02), VRX: 210.42 (+1.03), GILD: 103.69 (-1.52), AZN: 71.79 (-1.34), UTHR: 186.69 (-1.87), ABBV: 66.07 (+1.82), CELG: 118.71 (+2.62)

Why Healthcare is the Best Sector For Your Money
Brian Orelli, Sean Williams, and Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 26, 7:01AM CDT
The healthcare sector has been on fire the last few years, handily beating the broader markets. Much of the boost has come from biotechs, but even the broader Healthcare Select Sector SPDR ETF has nearly doubled the S&P 500 return since the...
HCA: 77.74 (+0.30), GILD: 103.69 (-1.52), UNH: 118.69 (+0.43), CVS: 101.58 (+0.70), XLV: 74.39 (-0.24)

I Called It: What's The Take Home Message?
Pharma Doc - at Seeking Alpha - Sun Apr 26, 12:52AM CDT

GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)

Bristol-Myers presents data on daclatasvir at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 6:30PM CDT

GILD: 103.69 (-1.52), BMY: 65.80 (-0.20)

Merck presents data on two HCV Phase 2s at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 6:05PM CDT

GILD: 103.69 (-1.52), MRK: 57.60 (+0.09)

Achillion presents data on HCV candidates at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 5:18PM CDT

GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)

Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT

GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)

Sovaldi-based regimens show high cure rates in HCV genotypes 2 - 5
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:22PM CDT

GILD: 103.69 (-1.52)

Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
Business Wire - Sat Apr 25, 12:00AM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of sofosbuvir-based regimens in chronic hepatitis C virus (HCV)-infected patients with genotypes 2, 3, 4 and 5. Results from the BOSON study of Sovaldi(R) (sofosbuvir 400 mg) in combination with ribavirin (RBV) or with pegylated interferon (PEG)/RBV demonstrated high cure rates across all patients with genotypes 2 and 3. Separately, results from a Phase 2 study demonstrate the safety and efficacy of Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) in patients with genotypes 4 or 5 infection. Data from both studies will be presented in oral sessions at the 50th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress(TM) 2015) in Vienna, Austria.
GILD: 103.69 (-1.52)

Final Glance: Biotechnology companies
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)

Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 5:28PM CDT
Merck reported encouraging data from an ongoing pivotal phase III program evaluating its grazoprevir/elbasvir.
BIIB: 401.71 (-28.57), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)

AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:36PM CDT
AbbVie's (ABBV) experimental HCV treatment is under priority review in the U.S. for the treatment of adults suffering from chronic genotype 4 HCV infection.
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AVEO: 1.92 (-0.08), ABBV: 66.07 (+1.82)

Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)

The Parade of Weak Earnings Reports Continues - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 24, 2:39PM CDT
The Parade of Weak Earnings Reports Continues - Earnings Preview
ACT: 295.41 (-2.95), F: 15.77 (+0.01), ETN: 68.58 (-0.52), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), XOM: 86.97 (-0.57), BAC: 15.64 (-0.05), UPS: 98.10 (-0.12), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10), AAPL: 130.28 (+0.61), VIAB: 70.74 (+0.04), MA: 90.72 (-0.16)

'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)

Midday Glance: Biotechnology companies
AP - Fri Apr 24, 12:36PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)

Early Glance: Biotechnology companies
AP - Fri Apr 24, 9:55AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 103.69 (-1.52), AMGN: 167.91 (-1.26), CELG: 118.71 (+2.62)

4 Nasdaq Stocks at All-Time Highs - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Apr 24, 9:27AM CDT
The Nasdaq touched an all-time on Thursday, breaching a record level achieved during the dot-com boom.
NVEE: 19.99 (+1.34), TSCO: 90.98 (-0.28), MNST: 141.78 (+1.42), BIIB: 401.71 (-28.57), DLTR: 81.14 (+0.13), GILD: 103.69 (-1.52), FB: 81.53 (-0.88), AMGN: 167.91 (-1.26), GOOGL: 573.66 (+16.20), ULTA: 157.08 (+0.09), MSFT: 47.87 (+4.53), INTU: 101.22 (-0.22), AAPL: 130.28 (+0.61)

Critical Alerts For Gilead Sciences, YPF, SPDR Gold Trust, SouFun and Nuance Communications Released By InvestorsObserver
PR Newswire - Fri Apr 24, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, YPF, GLD, SFUN and NUAN.
GILD: 103.69 (-1.52), NUAN: 15.25 (+0.28), GLD: 113.05 (-1.61), SFUN: 8.04 (-0.52), YPF: 30.15 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Boston STEM Expo Sparks Young Minds in Engineering

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...